To analyze the clinical efficacy of laparoscopy-assisted proximal gastrectomy with anti-reflux gastric tube reconstruction for patients with Siewert type II and III adenocarcinoma of esophagogastric junction (AEG).

The clinical data of 59 patients with Siewert type II and III AEG, who underwent laparoscopy-assisted proximal gastrectomy from June 2017 to June 2019, was analyzed retrospectively. Among these patients, 30 patients in group A received traditional gastric tube reconstruction before July 2018, while 29 patients in group B underwent anti-reflux gastric tube reconstruction from June 2018 to June 2019. Statistical analysis were performed by using SPSS 19.0 software. Measurement data such as perioperative indicators and RDQ scores were expressed as (±s), and were examined by using independent t test. Postoperative gastroesophageal reflux symptoms, reflux esophagitis (RE), gastroesophageal reflux disease (GERD) and other count data were analyzed by using χ² test. A P value of <0.05 was considered as statistically significant difference.

There was no statistically significant difference in the incidence of gastroesophageal reflux symptoms, RE and GERD between the two groups (P>0.05). The RDQ score of group A were significantly higher than that of group B 3 months and 6months after the operation [(8.83±4.00) vs. (4.28±3.16), P<0.05], [(8.60±4.09) vs. (4.83±3.04), P<0.05].

Compared with the traditional gastric tube reconstruction, anti-reflux management could achieve better clinical outcome, with less medical cost and simple and safe operative procedures, which is worthy of clinical promotion.